These co-expression patterns are highly relevant for the development of TASK-1 modulators against atrial fibrillation (AFib)3–5,18, obstructive and central sleep apnea (OSA and CSA)3,7 or pulmonary arterial hypertension (PAH)8,19–21. Here, KCNK3 is linked to central sleep apnea syndrome.